Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Testing delgocitinib cream for patients with vitiligo on the face

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study is looking at a condition called vitiligo, which is a skin disorder where patches of skin lose their natural color and become white. The study focuses specifically on vitiligo that affects the face. The treatment being tested is a cream called Anzupgo, which contains an active ingredient named delgocitinib. This cream is applied directly to the skin in the areas affected by vitiligo.

The purpose of this study is to find out whether delgocitinib cream could be a helpful treatment for people who have non-segmental vitiligo on their face. Non-segmental vitiligo means the white patches appear on both sides of the body rather than just one side. During the study, participants will apply the cream to their facial vitiligo patches for a period of 24 weeks. The study will measure changes in the amount and appearance of the white patches on the face and other parts of the body at different time points, including after 4 weeks, 12 weeks, and 24 weeks of treatment.

Throughout the study, doctors will check how well the treatment works by examining the size and severity of the vitiligo patches. They will also ask participants questions about how vitiligo affects their daily life and overall well-being. The study will monitor any unwanted effects that might occur during treatment. Some participants may have small skin samples taken at the beginning of the study and during treatment to help researchers understand how the cream works on the skin.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial treatment phase

    Upon joining the trial, you will begin applying delgocitinib cream (also known as Anzupgo 20 mg/g cream) to the vitiligo patches on your face.

    The cream is applied directly to the skin in the affected facial areas.

    You will continue this treatment throughout the trial period.

  2. Step 2

    Week 4 assessment

    At week 4, you will attend a visit where assessments will be performed.

    The extent of vitiligo on your face and body will be measured.

    You will be asked to complete questionnaires about your quality of life and well-being.

    A skin sample may be collected for laboratory analysis if changes in your facial vitiligo are observed.

  3. Step 3

    Week 12 assessment

    At week 12, you will attend another visit for assessments.

    The extent of vitiligo on your face and body will be measured again.

    You will complete questionnaires about your quality of life and well-being.

    Any side effects or adverse reactions will be recorded.

  4. Step 4

    Week 24 final assessment

    At week 24, you will attend the final visit of the trial.

    The extent of vitiligo on your face and body will be measured for the last time.

    You will complete final questionnaires about your quality of life and well-being.

    A skin sample may be collected for laboratory analysis if changes in your facial vitiligo are observed.

    All side effects and adverse reactions throughout the trial will be reviewed.

    This visit marks the completion of your participation in the trial.

Who can join the trial?

7 criteria

  • You must be able to provide written informed consent, which means you agree to participate in the trial by signing a document after understanding all the information about it
  • You must be 18 years of age or older at the time of screening
  • You must be able to understand, speak, and read Danish, as determined by the study doctor
  • You must have a clinical diagnosis of non-segmental vitiligo, which is a type of vitiligo that appears on both sides of the body, with patches affecting your face that cover at least 0.5% of your total body surface area (the total skin covering your body)
  • You must agree not to use any other treatments for vitiligo from the time you start screening until your final visit in the trial
  • You must be able and willing to follow all trial procedures, including applying the trial cream to the vitiligo patches on your face
  • If you are a woman of childbearing potential, which means a woman who could become pregnant, you must agree to use an acceptable method of birth control throughout the trial until the last time you apply the trial treatment

Who cannot join the trial?

3 criteria

  • The study does not list specific reasons why patients cannot participate
  • General exclusion criteria will be determined by the study doctors during the screening process
  • Your doctor will review your medical history and current health condition to decide if this study is right for you
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Delgocitinib is a cream that is applied directly to the skin. In this trial, it is being tested to see if it can help treat vitiligo, a condition that causes loss of skin color in patches, specifically on the face. The medication works by affecting certain processes in the immune system that may be involved in causing vitiligo.

What is already known about the treatment

Delgocitinib – Delgocitinib is a topical cream medication that is currently being studied in clinical trials for the treatment of vitiligo, a skin condition where patches of skin lose their natural color. This medication works at the molecular level by blocking specific enzymes called JAK (Janus kinase) proteins, which play a role in the immune system's attack on pigment-producing cells in the skin. By inhibiting these enzymes, delgocitinib may help restore normal skin pigmentation in affected areas, particularly on the face. It belongs to a class of drugs known as JAK inhibitors and is applied directly to the skin in the form of a cream.

Investigated diseases

Vitiligo – Vitiligo is a skin condition in which patches of skin lose their natural color and become white. This happens because the cells that produce skin pigment, called melanocytes, are destroyed or stop functioning. The white patches can appear anywhere on the body but are most noticeable on sun-exposed areas like the face, hands, and arms. Non-segmental vitiligo is the most common form, where white patches typically appear on both sides of the body in a symmetrical pattern. The condition can start at any age and may slowly spread over time. The patches do not cause physical discomfort but can affect a person's appearance and emotional well-being.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2025-523635-19-00Protocol codeDelVitoEstimated enrolment12 patientsSponsorGentofte Hospital

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.